-
Sep 30, 2024 | 
dermatologytimes.com | Bruce E. Strober |Aaron S. Farberg
Media Resources AcneAestheticsAlopeciaAtopic Dermatitis COVID-19Hidradenitis SuppurativaMelasmaNP and PAPediatric DermatologyPigmentary DisordersPractice ManagementPrecision Medicine and BiologicsPrurigo NodularisPsoriasisPsoriatic ArthritisRare DiseaseSkin CancerRosaceaVitiligoWound Care General Dermatology EczemaAlopeciaAestheticsVitiligoCOVID-19 Actinic Keratosis Precision Medicine and BiologicsRare DiseaseWound CareRosacea Psoriasis Psoriatic Arthritis Atopic Dermatitis MelasmaNP and...
-
Jun 26, 2024 | 
hcplive.com | Linda Gold |Bruce E. Strober
To watch the video series component of this episode, click here. 1:09 Comorbidities in Plaque Psoriasis5:11 Classifying the Severity of Plaque Psoriasis8:30 Laboratory Tests for Systemic Therapy13:22 Monitoring Systemic Therapy in Plaque Psoriasis16:50 New Oral Systemic Therapies for Plaque Psoriasis23:23 Efficacy Data on Deucravacitinib28:03 Long-term Safety Data of Deucravacitinib34:52 Selecting the Right Treatment for the Right Patient
-
Jun 26, 2024 | 
hcplive.com | Linda Gold |Bruce E. Strober
June 26, 2024Dermatologists have a comprehensive discussion on systemic therapies for the treatment of plaque psoriasis, covering monitoring practices, and long term efficacy data for novel oral agent deucravacitinib.
-
Jun 25, 2024 | 
hcplive.com | Linda Gold |Bruce E. Strober
June 25, 2024Linda Stein Gold, MD, and Bruce Strober, MD PhD, discuss classification and monitoring practices for patients with plaque psoriasis.
-
Jun 25, 2024 | 
consultantlive.com | Linda Gold |Bruce E. Strober
Beyond the Surface: Monitoring your Patients with Moderate to Severe Plaque Psoriasis - Episode 1Plaque Psoriasis: Comorbidities, Classification, and Testing PracticesPublished on: June 25, 2024Linda Stein Gold, MD, and Bruce Strober, MD PhD, discuss classification and monitoring practices for patients with plaque psoriasis. 1:09 Comorbidities in Plaque Psoriasis5:11 Classifying the Severity of Plaque Psoriasis8:30 Laboratory Tests for Systemic Therapy
-
Mar 7, 2024 | 
onlinelibrary.wiley.com | Bruce E. Strober |Andrew Blauvelt |Richard Warren |Kim A. Papp
INTRODUCTION The Janus kinase (JAK)-signal transducer and activator of transcription pathways play a major role in cytokine signalling in normal cellular processes and in immune-mediated diseases such as psoriasis.1, 2 JAK1,2,3 inhibitors are efficacious in patients with moderate-to-severe plaque psoriasis; however, JAK1,2,3 inhibitors are also associated with creatine phosphokinase (CPK) elevations, hyperlipidaemia and minimal hematologic abnormalities.3, 4 Therefore, it is important to...
-
Feb 23, 2024 | 
futuremedicine.com | Akimichi Morita |Bruce E. Strober |A Burden |Siew Eng Choon
What is this study about? Generalized pustular psoriasis (shortened to GPP) is a rare, potentially life-threatening disease in which pus-filled blisters or pustules may suddenly form all over the body. The drug spesolimab has been approved to treat worsening GPP (known as flares) in many countries. However, it was not known if spesolimab could prevent the symptoms of GPP.
-
Dec 20, 2023 | 
jamanetwork.com | Kim A. Papp |Kenneth Gordon |Bruce E. Strober |Joe Zhuo
Key PointsQuestion What constituted meaningful within-patient score improvement on the Psoriasis Symptoms and Signs Diary (PSSD) in a phase 3 trial among patients with psoriasis?
-
Dec 1, 2023 | 
hcplive.com | Bruce E. Strober |Benjamin Lockshin |Jennifer Soung
Bruce Strober, MD, PhD, FAAD: Ben, what are some of the pipeline therapeutics, future developments that you’re excited about with regard to psoriasis? Benjamin Lockshin, MD, FAAD: If you look at this space in terms of the treatment options, you’d think that we’re close to the goal line using a football analogy or that we’re in the red zone. I think we’re somewhere between the 50-yard line and approaching the red zone in terms of therapeutics.
-
Dec 1, 2023 | 
hcplive.com | Bruce E. Strober |Benjamin Lockshin |Jennifer Soung
Bruce Strober, MD, PhD, FAAD: Ben, can you share with me an anecdotal case of success that involves an IL-23 inhibitor, one that really was impactful for you? Benjamin Lockshin, MD, FAAD: There’s a couple situations, and I think one of the most remarkable stories is the patient who’s failed a number of treatments and then finally goes on a [IL-]23 and they’re clear again.
